CLK inhibitors (Oncodesign)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameCLK inhibitors (Oncodesign)
Drug Alias NameNanokinib compounds (Oncodesign)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsDown SyndromeAlzheimer DiseaseNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesOncodesign Services
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOncodesign Services
Active IndicationsN/A
Inactive IndicationsDown SyndromeAlzheimer DiseaseNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A